{"id":16413,"date":"2025-06-06T13:21:58","date_gmt":"2025-06-06T13:21:58","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=16413"},"modified":"2025-07-30T14:07:59","modified_gmt":"2025-07-30T14:07:59","slug":"une-nouvelle-association-therapeutique-reduit-de-moitie-le-risque-de-deces-chez-les-patients-atteints-dun-cancer-colorectal-metastatique-mute-brafv600e","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/essais-cliniques\/une-nouvelle-association-therapeutique-reduit-de-moitie-le-risque-de-deces-chez-les-patients-atteints-dun-cancer-colorectal-metastatique-mute-brafv600e\/","title":{"rendered":"Une nouvelle association th\u00e9rapeutique r\u00e9duit de moiti\u00e9 le risque de d\u00e9c\u00e8s chez les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique mut\u00e9 BRAFV600E"},"content":{"rendered":"<p>Des nouveaux r\u00e9sultats de <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39863775\/\" target=\"_blank\" rel=\"noopener\">l&rsquo;essai clinique de phase 3 BREAKWATER <\/a>montrent qu&rsquo;une association th\u00e9rapeutique comprenant BRAFTOVI\u00ae (encorafenib), cetuximab et une chimioth\u00e9rapie am\u00e9liore significativement la survie des patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique pr\u00e9sentant une modification g\u00e9n\u00e9tique sp\u00e9cifique appel\u00e9e mutation \u00a0BRAF V600E. Au cours de l&rsquo;essai, les patients recevant ce nouveau traitement ont v\u00e9cu deux fois plus longtemps, soit plus de 30 mois, que ceux recevant les traitements standard. Il a \u00e9galement retard\u00e9 la progression du cancer pendant une p\u00e9riode plus longue. C&rsquo;est la premi\u00e8re fois qu&rsquo;une th\u00e9rapie cibl\u00e9e pr\u00e9sente des avantages aussi importants pour des patients nouvellement diagnostiqu\u00e9s avec ce type de mutation. Les experts estiment que ces r\u00e9sultats pourraient modifier la mani\u00e8re dont cette forme agressive de cancer colorectal est trait\u00e9e. La nouvelle th\u00e9rapie combin\u00e9e est d\u00e9j\u00e0 approuv\u00e9e sous conditions aux \u00c9tats-Unis, et Pfizer d\u00e9posera une demande aupr\u00e8s de Sant\u00e9 Canada et de l&rsquo;Agence canadienne des m\u00e9dicaments au cours des mois d&rsquo;\u00e9t\u00e9. Bien que les effets secondaires soient similaires \u00e0 ceux de la chimioth\u00e9rapie, le traitement offre un nouvel espoir aux patients et \u00e0 leurs familles.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Des nouveaux r\u00e9sultats de l&rsquo;essai clinique de phase 3 BREAKWATER montrent qu&rsquo;une association th\u00e9rapeutique comprenant BRAFTOVI\u00ae (encorafenib), cetuximab et une chimioth\u00e9rapie am\u00e9liore significativement la survie des patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique pr\u00e9sentant une modification g\u00e9n\u00e9tique sp\u00e9cifique appel\u00e9e mutation \u00a0BRAF V600E. Au cours de l&rsquo;essai, les patients recevant ce nouveau <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/essais-cliniques\/une-nouvelle-association-therapeutique-reduit-de-moitie-le-risque-de-deces-chez-les-patients-atteints-dun-cancer-colorectal-metastatique-mute-brafv600e\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":16423,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[57,98],"tags":[],"class_list":["post-16413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-essais-cliniques","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=16413"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/16413\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/16423"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=16413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=16413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=16413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}